Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea

Ethan C. Haese; Van C. Thai; Charlene M. Kahler

doi:10.3390/vaccines9070804

Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea

Ethan C. Haese, Van C. Thai, Charlene M. Kahler

Research output: Contribution to journal › Review article › peer-review

14 Citations (Scopus)

Abstract

The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list of antimicrobial resistant pathogens and is urgently seeking the development of new intervention strategies. N. gonorrhoeae causes 86.9 million cases globally per annum. The effects of gonococcal disease are seen predominantly in women and children and especially in the Australian Indigenous community. While economic modelling suggests that this infection alone may directly cost the USA health care system USD 11.0–20.6 billion, indirect costs associated with adverse disease and pregnancy outcomes, disease prevention, and productivity loss, mean that the overall effect of the disease is far greater still. In this review, we summate the current progress towards the development of a gonorrhea vaccine and describe the clinical trials being undertaken in Australia to assess the efficacy of the current formulation of Bexsero® in controlling disease.

Original language	English
Article number	804
Journal	Vaccines
Volume	9
Issue number	7
DOIs	https://doi.org/10.3390/vaccines9070804
Publication status	Published - Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines9070804Licence: CC BY

Cite this

@article{d49eb237fcf24153ba90958862a1a309,

title = "Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea",

abstract = "The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list of antimicrobial resistant pathogens and is urgently seeking the development of new intervention strategies. N. gonorrhoeae causes 86.9 million cases globally per annum. The effects of gonococcal disease are seen predominantly in women and children and especially in the Australian Indigenous community. While economic modelling suggests that this infection alone may directly cost the USA health care system USD 11.0–20.6 billion, indirect costs associated with adverse disease and pregnancy outcomes, disease prevention, and productivity loss, mean that the overall effect of the disease is far greater still. In this review, we summate the current progress towards the development of a gonorrhea vaccine and describe the clinical trials being undertaken in Australia to assess the efficacy of the current formulation of Bexsero{\textregistered} in controlling disease.",

keywords = "Antimicrobial resistance, Gonorrhea, Multi-drug resistance, Neisseria gonorrhoeae, Sexually transmitted infections, Vaccine development",

author = "Haese, {Ethan C.} and Thai, {Van C.} and Kahler, {Charlene M.}",

year = "2021",

month = jul,

doi = "10.3390/vaccines9070804",

language = "English",

volume = "9",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "7",

}

TY - JOUR

T1 - Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea

AU - Haese, Ethan C.

AU - Thai, Van C.

AU - Kahler, Charlene M.

PY - 2021/7

Y1 - 2021/7

N2 - The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list of antimicrobial resistant pathogens and is urgently seeking the development of new intervention strategies. N. gonorrhoeae causes 86.9 million cases globally per annum. The effects of gonococcal disease are seen predominantly in women and children and especially in the Australian Indigenous community. While economic modelling suggests that this infection alone may directly cost the USA health care system USD 11.0–20.6 billion, indirect costs associated with adverse disease and pregnancy outcomes, disease prevention, and productivity loss, mean that the overall effect of the disease is far greater still. In this review, we summate the current progress towards the development of a gonorrhea vaccine and describe the clinical trials being undertaken in Australia to assess the efficacy of the current formulation of Bexsero® in controlling disease.

AB - The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list of antimicrobial resistant pathogens and is urgently seeking the development of new intervention strategies. N. gonorrhoeae causes 86.9 million cases globally per annum. The effects of gonococcal disease are seen predominantly in women and children and especially in the Australian Indigenous community. While economic modelling suggests that this infection alone may directly cost the USA health care system USD 11.0–20.6 billion, indirect costs associated with adverse disease and pregnancy outcomes, disease prevention, and productivity loss, mean that the overall effect of the disease is far greater still. In this review, we summate the current progress towards the development of a gonorrhea vaccine and describe the clinical trials being undertaken in Australia to assess the efficacy of the current formulation of Bexsero® in controlling disease.

KW - Antimicrobial resistance

KW - Gonorrhea

KW - Multi-drug resistance

KW - Neisseria gonorrhoeae

KW - Sexually transmitted infections

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=85111568251&partnerID=8YFLogxK

U2 - 10.3390/vaccines9070804

DO - 10.3390/vaccines9070804

M3 - Review article

C2 - 34358218

SN - 2076-393X

VL - 9

JO - Vaccines

JF - Vaccines

IS - 7

M1 - 804

ER -

Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this